Late Breaking Abstract - Depemokimab efficacy/safety in patients with asthma on medium/high-dose ICS: The Phase IIIA randomised SWIFT-1/2 studies

<bold>Background:</bold> Depemokimab is the first ultra-long-acting biologic to have enhanced binding affinity for interleukin-5 (IL-5) with high potency inhibition, enabling six-month dosing intervals for patients with asthma. <bold>Methods:</bold> The randomised double-blind placebo-controlled multicentre SWIFT-1/2 studies evaluated depemokimab efficacy/safety in patients with asthma receiving medium/high-dose ICS (<bold>Fig. 1</bold>). <bold>Results:</bold> Annualised clinically significant exacerbation rate over 52 weeks in SWIFT-1/2 was significantly lower (58%/48%; p<0.001) for depemokimab vs placebo (<bold>Fig. 2</bold>). Proportions of patients with an adverse event (AE) were similar for depemokimab vs placebo in SWIFT-1 (73% vs 73%) and lower in SWIFT-2 (72% vs 78%); AEs leading to discontinuation/withdrawal were <3% across groups in both trials. A smaller proportion of depemokimab patients had a serious AE vs placebo (SWIFT-1: 6% vs 17%; SWIFT-2: 7% vs 10%). <bold>Conclusions:</bold> Depemokimab significantly reduced exacerbations and was well tolerated in patients with asthma with type 2 inflammation recognised by blood eosinophil count. <bold>Funding:</bold> GSK 206713/213744; <ext-link>NCT04719832</ext-link>/04718103 <fig><object-id>erj;64/suppl_68/RCT3718/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <fig><object-id>erj;64/suppl_68/RCT3718/F2</object-id><object-id>F2</object-id><object-id>F2</object-id><graphic></graphic></fig>